APC and colorectal carcinoma: In particular, niclosamide (0.4, 2 and 10 μMol/L) was reported to inhibit the Wnt/β-catenin signaling pathway, whose aberrant activation occurs in approximately 80% of sporadic CRCs [65], and proliferation of the human CRC cell lines HCT-116, HT-29 and Caco2, regardless of mutations in the key regulator APC [34].